Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 10 6 cells/kg (phase I = three patients; phase II = 14 patients). The best overall response rate (ORR) was 100% ...
Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments. The work is published in the journal ...
In a recent study published in the International Journal of Molecular Sciences, researchers reported that lentiviral pseudovirions pseudotyped with severe acute respiratory syndrome coronavirus 2 ...
Technologies used for cell and gene therapy development have come a long way but there are still important challenges associated with lentivirus manufacture. GMP plasmids account for a substantial ...
Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with ...
Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments. Researchers at the Korea Research ...
The LV Edge Packaging System has recently been launched to improve cost efficiency and reduce the supply chain risk of lentiviral production. The company claims the ready-to-transfer system minimizes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results